![]() |
|
|
Forward to a colleague |
||
Product Overview ![]() Lab professionals have twice as much upper limb disorders (URLD) as employees in general. The risk of Repetitive Strain Injury (RSI) increases, when pipetting over 1.5 hours/day. The strain will also have a negative impact on the accuracy and precision. Read more..... Click Here Access Full Stories Enzo Biochem has lodged an appeal after its patent infringement claims against Applied Biosystems (ABI) were dismissed on Friday in a summary judgement... Read Cisbio to brighten screening technology Cisbio has entered into a partnership agreement with Lumiphore to gain access to new fluorescence reporter molecules for use in its high throughput (HT) screening assays... Read AstraZeneca to help Biovator replace in vivo allergy testing AstraZeneca (AZ) is to assist Biovator in the development of its in vitro test for identifying potential allergens that could replace many experiments on animals... Read Industry news in brief - week 37 LabTechnologist.com brings you its round up of industry news, with new developments at Applied Biosystems, Empire Genomics, NanoSight, Q Chip and Thermo fisher Scientific... Read Imaging protease activity US researchers have developed a molecular probe that can light up tumour cells within living animals and enable direct imaging of cysteine protease activity... Read |
||||||||||||||||||
All News Headlines for: September | August | July |
||||||||||||||||||
|
Related Industry News Evotec hives off chemical development biz German firm Evotec has sold off its chemical and pharmaceutical development (CPD) business along with the associated facilities in the UK... Read Crospon to make drug delivery smarter Irish start-up Crospon has licensed a 'smart' drug delivery skin patch technology from HP Labs that uses inkjet printing technology to deliver drugs under the skin... Read Second new class of HIV drug given thumbs up Merck & Co.'s integrase inhibitor, the first in a new class of HIV drug, looks likely to win approval in the near future, following a recommendation to regulators... Read FDA probe ghost stops haunting MDS Pharma It seems that the ghost of the US Food and Drug Administration (FDA) probe has stopped haunting MDS Pharma as the firm posted encouraging financial results in the third quarter... Read
|
||||||||||||||||||
|
|||||
Forward to a colleague |
|||||
To continue to receive this newsletter in your inbox, please add newsletter@LabTechnologist.com to your address book |
||
Update preferences | Change your email address | Unsubscribe |
||
Contact us: Advertising | Recruitment | Privacy policy | Terms & conditions | Feedback |
||
| © 2007 - Decision News Media S.A.S - All Rights Reserved Le Belem - 355, rue Vendemiaire - 34000 Montpellier - France http://www.decisionnewsmedia.com |
||